Traders/Users: Online

Biotech Stocks

Fundamental and Chart Analysis

Tech Stocks

For long and short term


With NYSE, Nasdaq and OTCBB companies


We write opinion articles for the leading companies


We have more than 10 years of experience in the financial markets

Welcome to bolsaTrading. A website for those who want to be informed about world financial markets.

Our readers could find monthly recommendations of international shares by means of charts as well as fundamentals analysis. Investors buy and/or sell at their own risk. bolsaTrading has zero connection to Wall Street.


Neomedia Technologies: Apple and Microsoft be interested?

A consortium formed by Microsoft and Apple might be interested in several patents for the company Neomedia (OTC:NEOM) suggest different people within the sector. It must be remembered that the company Neomedia technologies has more than 500 patents that could be valued according to some experts in more than $500MM. This reason could give an explanation to the strong increase in volume that leads the company in the last four days. This reason could assess the company Neomedia in more than $800MM.

About Neomedia Technologies
NeoMedia Technologies, Inc. (NeoMedia) utilizes the mobile phone by leveraging barcodes (printed symbols) as a mechanism to link brands, advertisers, carriers, retailers and consumers using the mobile Internet. With the barcode ecosystem technology, NeoMedia transforms mobile phones with cameras into barcode scanners, which provide instant access to mobile Web content whenever a barcode is scanned. NeoMedia provides the infrastructure to facilitate mobile barcode scanning and its associated commerce globally. The mobile barcode ecosystem software reads and transmits data from one-dimensional (1D) and two-dimensional (2D) barcodes to its intended destination. The code management and clearinghouse platforms create, connect, record, and transmit the transactions embedded in the barcodes. In order to provide mobile marketing solutions, NeoMedia also offers barcode scanning hardware that reads barcodes displayed on mobile phone screens.

Disclosure: I am long NEOM..

Additional disclosure: This article is intended for informational and entertainment use only and should not be construed as professional investment advice. Always do you own complete due diligence before buying and selling any stock.


3 Biotech Stocks Undervalued

Approaching the ASCO conference is a good opportunity to take positions in 3 biotechnology companies undervalued. Every year the percentage of return and growth as they approach this time is usually high.
Telik, Inc. (TELK), The price to book ratio is 0.50. The company has a drug in Phase 2 TELINTRA ® Trial in Myelodysplastic Syndrome, in Phase 2 Trial in Severe Chronic Neutropenia and Phase 1 Combination Trial with Revlimid in Myelodysplastic Syndrome. He also continues his research in Telcyta ® while in Phase 2 trial using Telcyta ® in MCL, DLBCL & MM.

Columbia Laboratories Inc. (CBRX) The price to sales ratio is 1.76. The company has Prochieve ® 8% (Reduction of Risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy and NDA filed April 2011), COL-1777 Indication: Gynecological Procedures Associated with pain in Phase II and COL -2401 for bacterial vaginosis (Pre-clinical)

BioSante Pharmaceuticals, Inc. (BPAX) The price to book ratio is 4.14. The company has in Phase III LibiGel ® Efficacy Results, Cancer Vaccines: Chronic Myeloid Leukemia CML in Phase II clinical trial, Acute Myeloid Leukemia (AML) in Phase II and Phase II Pancreatic Cancer in, The Pill-Plus ™ is an oral Currently in Development contraceptive in Phase II.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.